HSPC159 is a novel human galectin-related protein that has been shown to be involved in carcinogenesis. Little is known about HSPC159 expression and function in breast cancer. Herein we showed that HSPC159 was aberrantly expressed in both breast cancer cell lines and tumor tissues and that its expression was associated with poor prognosis of breast cancer patients. Using gain-and loss-of-function methods we found that HSPC159 enhanced breast cancer cell proliferation and metastasis in vitro and in vivo. IHC, immunohistochemistry; N-cadherin, neural cadherin.
galectins play important functions in several aspects of cancer biology, including proliferation, apoptosis, invasion, metastasis and angiogenesis of cancer cells, indicating that galectins might modulate tumor progression and influence disease outcome. [2] [3] [4] HSPC159 is a novel human galectin-related protein (also known as GRP) that is mapped to human chromosome 2p13. The HSPC159 gene was originally deduced by partial sequence alignment and confirmed by a full-length sequence for an mRNA isolated from CD34+ hematopoietic stem cells. 5 The HSPC159 sequence is composed of 5 exons with exon/intron junctions located in positions generally conserved across the galectin family. 6 HSPC159 comprises only 1 conserved CRD with 38 additional N-terminal residues and shares consensus amino acids at 51 of the 64 most highly conserved residues in other galectins. 7 However, human HSPC159 shows a serious sequence deviation at 5 of the 7 highly conserved carbohydrate recognition segments, leading to them lacking b-galactoside binding activity. The biological role of human HSPC159 has so far not been elucidated completely. HSPC159 has been shown to be involved in carcinogenesis. Knockdown of HSPC159 could increase the sensitivity of colon cancer cells to methotrexate, 8 implying its oncogenic potential. By conducting microarray analysis, Koch and Wiese 9 showed that HSPC159 was downregulated in cervical cancer tissues and HSPC159 was identified as 1 of potential biomarker genes for cervical cancer. 9 However, Zhang et al 10 indicated that miR-9 could repress tumorigenesis of cervical adenocarcinoma by targeting HSPC159, implying that HSPC159 might exert distinct and even opposite functions in cervical cancer.
To date, however, there are no reports concerning the expression and biological functions of HSPC159 in human breast cancer.
In the present study, we found that HSPC159 was upregulated in breast cancer and correlated with clinicopathological factors of breast cancer patients. HSPC159 depletion effectively suppressed the proliferation and metastasis of breast cancer cells in vitro and in vivo. Moreover, HSPC159 was found to induce EMT and the Factin polymerization process of breast cancer cells. We also showed that PI3K/Akt signaling was involved in the oncogenic effects of HSPC159 in breast cancer. Our study might present valuable information for elucidating the pathogenesis mechanism of breast cancer and provide a potential biomarker for breast cancer therapy.
| MATERIALS AND METHODS

| Patient samples
Ninety-six human invasive breast carcinoma specimens and adjacent non-tumor tissues were collected at the time of surgical resection from and percentage of positive cells (0; 1, 1%-25%; 2, 26%-50%; 3, 51%-75%; 4, 76%-100%). These scores were added to produce the final score: high (score ≥4) and low or none (score 0-3). 
| Cell culture and transfection
| RNA extraction and quantitative reverse transcription PCR (qRT-PCR)
Total RNA was extracted from cell lines and tissues using Trizol (Invitrogen) and cDNA was synthesized using the ReverTra Ace qPCR RT Kit (Toyobo, Osaka, Japan). Real-time quantitative PCR was carried out using FastStart Universal SYBR Green Master (Roche Diagnostic GmbH, Mannheim, Germany). Relative expression of HSPC159 was detected using the 2 ÀDDCT method.
| Cell counting Kit-8 assay
Cell proliferation was measured at 24, 48, and 72 hours after transfection. CCK-8 solution (Dojindo, Gaithersburg, MD, USA) was added to the culture medium, followed by an incubation of 4 hours and the optical density was read at 450 nm. 
| EdU assay
| Immunofluorescence
Cells were grown on coverslips, fixed in 4% paraformaldehyde for 20 minutes. Primary antibody was carried out overnight at 4°C. The antibodies used were E-cadherin and N-cadherin (1:300; Santa Cruz Biotechnology). Cells were costained with DAPI to detect nuclei. The results were analyzed using fluorescence microscopy.
| Xenograft model experiment
Four-week-old SCID mouse were purchased from Beijing HFK Bioscience Co., Ltd (Beijing, China). All animal work procedures were approved by the Ethics Committee of Weifang Medical University.
MDA-MB-231 cells transfected stably with shRNA-HSPC159 or shnegative control were injected into the fat pads or the through tail vein (4 9 10 6 cells per mouse), respectively, into SCID mice (6 for each group). Tumor sizes were measured using a caliper every 7 days when the tumors were apparent. All mice were killed after 5 weeks (fat pads xenograft group) or 8 weeks (lung metastases xenograft group), and the tumor nodules and lungs of mice were isolated.
Tumor volume was calculated according to the following equation:
Tumor volumeðmm 3 Þ ¼ lengthðmmÞ Â widthðmmÞ 2 =2:
Lung tissues were fixed with formalin, embedded in paraffin and H&E staining serial slides were carried out to detect micrometastases.
| Cellular F-actin measurement
Breast cancer cells were suspended in medium supplemented with 10 mmol/L HEPES (pH 7.2) and 2% (w/v) BSA at a concentration of 2.5 9 10 3 cells per mL and incubated at 37°C for 3 hours. Next, these cells were stimulated by 10 ng/mL EGF at 37°C for the indi- 
| Statistical analysis
Statistical significance was determined with Student's t test, 1-way analysis of variance or a chi-squared test as appropriate. Survival rates were calculated by the Kaplan-Meier method and compared by the log-rank test. Each experiment was repeated 3 times. Statistical analyses were analyzed using GraphPad Prism 5 software (GraphPad Software, Inc., San Diego, CA, USA). P < .05 was considered to be statistically significant.
| RESULTS
| Upregulation of HSPC159 in breast cancer tissues and cell lines
Immunohistochemistry analysis was carried out to investigate | 2155 increased in cancer tissues compared with matched ANT (P < .05; Figure 1C ). These results showed that expression of HSPC159 was increased in both clinical primary breast cancer tissues and in human highly invasive breast cancer cell lines.
| Correlation of HSPC159 with clinicopathological features
In order to gain a better understanding of the influences of HSPC159 on breast cancer, we evaluated the associations between HSPC159 expression and clinicopathological factors. Patients were divided into the HSPC159 high-expression group (n = 52) and the HSPC159 low-or no-expression group (n = 44) based on IHC scores. As listed in Table 1 , high HSPC159 expression was strongly correlated with tumor size (P = .040), clinical stage (P = .043), lymph node metastasis (P = .021), and tumor differentiation (P = .012).
These results confirmed that high expression of HSPC159 was correlated with progression and metastasis of human breast cancer.
| High expression of HSPC159 predicted a poor prognosis of breast cancer patients
Kaplan-Meier analysis using the log-rank test was carried out to 
| HSPC159 promoted breast cancer cell proliferation in vitro and in vivo
To monitor transfection efficiency, western blot was carried out to determine HSPC159 expression at 48 hours after transfection. As group was obviously slower than that in the NC group ( Figure 2I ).
Immunohistochemistry for Ki-67 showed tumor cells in the control group had more proliferative activity compared with those in the sh-HSPC159 group ( Figure 2J ). In conclusion, these results showed that HSPC159 promoted tumor growth in vitro and in vivo.
| Downregulation of HSPC159 inhibited migration and invasion abilities of breast cancer cells in vitro and in vivo
Given that HSPC159 was highly expressed in metastatic breast cancer tissues and cell lines, we carried out cell migration and invasion assay to MDA-MB-231 cells also showed reduced migration and invasion capacity after shRNA transfection compared with negative control cells ( Figure 3C ). The metastatic properties of breast cancer cells were analyzed in vivo through a xenograft transplant model in SCID mice. Metastatic foci in mouse lungs were examined through H&E staining slides. As shown in Figure 3D ,E, the number of lung metastatic nodules in the shRNA-HSPC159 group was decreased compared to the negative control group (P < .05). These data demonstrated that HSPC159 had a pivotal role in mediating breast cancer cell invasion and metastasis.
| HSPC159 knockdown suppressed the EMT process of breast cancer cells
Epithelial-mesenchymal transition plays an important role in cancer cell migration and invasion. In order to determine the relationship between HSPC159 expression and EMT, we examined the expression of key Figure 4C ). We then examined EMT-associated transcription factors, and our results showed that silenced HSPC159 inhibited the expression of Snail and Twist, but had no effect on Slug and ZEB1 compared with the control group in MDA-MB-231 cells ( Figure 4D) . Meanwhile, the expression of Snail and Twist was upregulated in overHSPC159/MCF-7 cells ( Figure 4E ).
These data indicated that HSPC159 could regulate breast cancer cell EMT processes through Snail and Twist. showed that LY294002 significantly suppressed the phosphorylation of Akt (Thr308 and Ser473) compared with the control group (Figure 6A,B) . These results showed that HSPC159 was involved in the PI3K/Akt pathway in breast cancer.
| Reduction of HSPC159 impaired F-actin polymerization in breast cancer cells
To explore the role of HSPC159 in regulating the proliferation, migration and invasion effect of breast cancer cells through PI3K/ Akt, we transfected HSPC159 full-length plasmid into MCF-7 cell lines; the proliferation, migration and invasion ability was increased ( Figure 6C -E). Cells were then also treated with PI3K inhibitor LY294002, and cell proliferation, migration and invasion was inhibited ( Figure 6C-E) . These results clearly demonstrated that HSPC159 promoted cell proliferation, migration, and invasion through PI3K/ Akt signaling. Actin polymerization and subsequent formation of membrane protrusions play an important role in cell migration. 14, 15 This actin cytoskeleton remodeling is crucial for the motility and chemotaxis of cancer cells and consequently influences the metastatic ability of these cells. 16 Our findings showed that HSPC159 took part in actin polymerization to regulate cytoskeletal rearrangement, which plays an important role in migration and invasion of breast cancer cells. LIMK and cofilin regulated chemoattractant-induced actin polymerization that is crucial for motility. 17, 18 Our studies also suggested that HSPC159 enhanced LIMK and cofilin phosphorylation, thus promoting actin polymerization. Taken together, our results suggest that HSPC159 acts upstream of LIMK/cofilin and mediates actin polymerization.
Furthermore, many studies have shown that the PI3K/Akt pathway plays an important role in malignant tumor progression, and that activation of Akt is associated with cell proliferation, survival, migration and invasion. 19, 20 In order to explore the mechanism by which HSPC159 promotes growth and invasion in breast cancer cells, we measured the phosphorylation of Akt to investigate the activation of 
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